My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 388

    1.

    Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.

    Zander M, Christiansen A, Madsbad S, Holst JJ.

    Diabetes Care. 2004 Aug;27(8):1910-4.PMID: 15277416 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

    Toft-Nielsen MB, Madsbad S, Holst JJ.

    Diabetes Care. 1999 Jul;22(7):1137-43.PMID: 10388979 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.

    Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ.

    Diabetes Care. 2001 Apr;24(4):720-5.PMID: 11315837 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

    Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.

    Diabetes Care. 1998 Nov;21(11):1925-31.PMID: 9802745 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.

    Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S.

    Diabetes Care. 1996 Aug;19(8):857-63.PMID: 8842604 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes.

    Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D.

    Diabetes Care. 2003 Oct;26(10):2835-41.PMID: 14514588 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.

    Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst JJ, Krarup T.

    Diabetes Care. 2003 Sep;26(9):2581-7.PMID: 12941722 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.

    Larsen J, Hylleberg B, Ng K, Damsbo P.

    Diabetes Care. 2001 Aug;24(8):1416-21.PMID: 11473079 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.

    Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA.

    Exp Clin Endocrinol Diabetes. 1998;106(2):103-7.PMID: 9628239 [PubMed - indexed for MEDLINE]Related articles

    10.

    Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

    Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.

    Diabet Med. 1998 Nov;15(11):937-45.PMID: 9827848 [PubMed - indexed for MEDLINE]Related articles

    11.

    Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

    Zander M, Madsbad S, Madsen JL, Holst JJ.

    Lancet. 2002 Mar 9;359(9309):824-30.PMID: 11897280 [PubMed - indexed for MEDLINE]Related articles

    12.

    GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.

    Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B.

    Diabetes Care. 1997 Dec;20(12):1874-9.PMID: 9405910 [PubMed - indexed for MEDLINE]Related articles

    13.

    The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients.

    Juntti-Berggren L, Pigon J, Karpe F, Hamsten A, Gutniak M, Vignati L, Efendic S.

    Diabetes Care. 1996 Nov;19(11):1200-6.PMID: 8908380 [PubMed - indexed for MEDLINE]Related articles

    14.

    Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.

    Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR.

    Clin Sci (Lond). 1998 Sep;95(3):325-9.PMID: 9730852 [PubMed - indexed for MEDLINE]Related articles

    15.

    Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.

    Larsen PJ, Wulff EM, Gotfredsen CF, Brand CL, Sturis J, Vrang N, Knudsen LB, Lykkegaard K.

    Diabetes Obes Metab. 2008 Apr;10(4):301-11.PMID: 18333889 [PubMed - indexed for MEDLINE]Related articles

    16.

    Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

    Rachman J, Barrow BA, Levy JC, Turner RC.

    Diabetologia. 1997 Feb;40(2):205-11.PMID: 9049482 [PubMed - indexed for MEDLINE]Related articles

    17.

    Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes.

    Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B.

    Crit Care Med. 2004 Mar;32(3):848-51.PMID: 15090972 [PubMed - indexed for MEDLINE]Related articles

    18.

    Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

    Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.

    Diabetes Care. 1996 Jun;19(6):580-6.PMID: 8725855 [PubMed - indexed for MEDLINE]Related articles

    19.

    Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.

    Egan JM, Meneilly GS, Habener JF, Elahi D.

    J Clin Endocrinol Metab. 2002 Aug;87(8):3768-73.PMID: 12161508 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.

    Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W.

    Regul Pept. 2004 Apr 15;118(1-2):89-97. Erratum in: Regul Pept. 2005 Nov 15;131(1-3):111. Gallwitz, J Baptist [corrected to Gallwitz, Baptist]. PMID: 14759561 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity